eFFECTOR Therapeutics, Inc.

Tyra Biosciences' TYRA-300 Shows Promise in Metastatic Urothelial Cancer

7 months ago

• TYRA Biosciences reported positive interim results for TYRA-300 in metastatic urothelial cancer (mUC) from the SURF301 Phase 1/2 study, demonstrating notable anti-tumor activity. • The company's IND was cleared for a Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301), with plans to initiate the study in Q1 2025. • TYRA-300 is also on track for a Phase 2 IND submission for non-muscle invasive bladder cancer (NMIBC) by the end of 2024, expanding its clinical development. • Doug Warner, MD, was appointed as Chief Medical Officer, bringing extensive experience in oncology and skeletal disease drug development to Tyra Biosciences.